Cytokines in cancer.

Abstract

Cytokines are proteins used by immune cells to communicate with each other and with cells in their environment.

The pleiotropic effects of cytokine networks are determined by which cells express cytokines and which cells express cytokine receptors, with downstream outcomes that can differ based on cell type and environmental cues.

Certain cytokines, such as interferon (IFN)-γ, have been clearly linked to anti-tumor immunity, while others, such as the innate inflammatory cytokines, promote oncogenesis. Here we provide an overview of the functional roles of cytokines in the tumor microenvironment.

Although we have a sophisticated understanding of cytokine networks, therapeutically targeting cytokine pathways in cancer has been challenging.

We discuss current progress in cytokine blockade, cytokine-based therapies, and engineered cytokine therapeutics as emerging cancer treatments of interest.

COI Statement

Declaration of interests S.K.D. received research funding unrelated to this project from Novartis, Bristol-Myers Squibb, Takeda; is a founder, science advisory board member, and equity holder in Kojin; and has equity in Axxis Bio.

References:

Dranoff G. (2004). Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11–22. 10.1038/nrc1252.
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, and Mulligan RC (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539–3543. 10.1073/pnas.90.8.3539.
Berns AJ, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffee EM, Lazenby AJ, Levitsky HI, and Marshall FF (1995). Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 6, 347–368. 10.1089/hum.1995.6.3-347.
Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, et al. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 105, 3005–3010. 10.1073/pnas.0712237105.
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, et al. (2003). Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100, 4712–4717. 10.1073/pnas.0830997100.

Article info

Journal issue:

Volume: 43
Issue: 1

Doi:

10.1016/j.ccell.2024.11.011

More resources:

Elsevier Science

Full Text Sources

Paid

MedlinePlus Health Information

Medical

Free resource

PubMed Central